Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Hanmi-sonefpeglutide

More Like This

PR Newswire associated0

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

PR Newswire associated0

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

PR Newswire associated0

Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

PR Newswire associated0

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

PR Newswire associated0

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications

PR Newswire associated0

Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions